Trump's first presidential cognitive assessment was in 2018, when he took the Montreal Cognitive Assessment (MoCA) -- a brief ...

Hearing imaginary voices is a common but mysterious feature in schizophrenia. Up to 80 percent of people with the disease experience auditory hallucinations—hearing voices or other sounds when there ...

Not enough is known about how the disease affects women, who are more likely than men to be overlooked—and more likely to develop the disease in midlife. Schizophrenia is a general term for a group of ...

For decades, scientists have suspected that the voices heard by people with schizophrenia might be their own inner speech gone awry. Now, researchers have found brainwave evidence showing exactly how ...

On his mental health journey, Gucci Mane has his wife by his side. The Atlanta rap legend, who released his second memoir "Episodes" on Oct. 14, has revealed that he has been diagnosed with bipolar ...

For Henry Cockburn, the onset of schizophrenia felt like pure common sense. It was February 2002, and the 20-year-old art student had strayed from the University of Brighton to satisfy his desire for ...

Schizophrenia is a serious mental disorder involving changes in perception, thoughts, and behaviors. It typically involves a disconnection from reality, in which a person experiences hallucinations ...

Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Background: The Box and Block Test (BBT) is recognized for assessing manual dexterity; however, its reliability and validity, specifically for individuals with schizophrenia spectrum disorders, remain ...

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has failed a pivotal test intended to support expanding its use, a ...